How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis by Barin, Laura et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
How do patients enter the healthcare system after the first onset of multiple
sclerosis symptoms? The influence of setting and physician specialty on
speed of diagnosis
Barin, Laura ; Kamm, Christian P ; Salmen, Anke ; Dressel, Holger ; Calabrese, Pasquale ; Pot,
Caroline ; Schippling, Sven ; Gobbi, Claudio ; Müller, Stefanie ; Chan, Andrew ; Rodgers, Stephanie ;
Kaufmann, Marco ; Ajdacic-Gross, Vladeta ; Steinemann, Nina ; Kesselring, Jürg ; Puhan, Milo A ; von
Wyl, Viktor
Abstract: BACKGROUND Diagnosing multiple sclerosis (MS) early is crucial to avoid future disability.
However, potentially preventable delays in the diagnostic cascade from contact with a physician to definite
diagnosis still occur and their causes are still unclear. OBJECTIVE To identify the possible causes of
delays in the diagnostic process. METHODSWe analyzed the data of the Swiss MS Registry. With logistic
regression, we modeled the time from the first contact to the first consultation (contact-to-evaluation time,
￿1 month/>1 month) and the evaluation-to-diagnosis time (￿6 months/>6 months). Potential factors were
health system characteristics, sociodemographic variables, first symptoms, and MS type. RESULTS We
included 522 participants. Mostly, general practitioners (67%) were contacted first, without delaying the
diagnosis. In contrast, first symptoms and MS type were the major contributors to delays: gait problems
were associated with longer contact-to-evaluation times, depression as a concomitant symptom with longer
evaluation-to-diagnosis times, and having primary progressive MS prolonged both phases. In addition,
living in mountainous areas was associated with longer contact-to-evaluation times, whereas diagnosis
after 2000 was associated with faster diagnoses. CONCLUSION For a quicker diagnosis, awareness of
MS as a differential diagnosis of gait disorders and the co-occurrence of depression at onset should be
raised, and these symptoms should be attentively followed.
DOI: https://doi.org/10.1177/1352458518823955
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-175190
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International
(CC BY-NC 4.0) License.
Originally published at:
Barin, Laura; Kamm, Christian P; Salmen, Anke; Dressel, Holger; Calabrese, Pasquale; Pot, Caroline;
Schippling, Sven; Gobbi, Claudio; Müller, Stefanie; Chan, Andrew; Rodgers, Stephanie; Kaufmann,
Marco; Ajdacic-Gross, Vladeta; Steinemann, Nina; Kesselring, Jürg; Puhan, Milo A; von Wyl, Viktor
(2019). How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms?
The influence of setting and physician specialty on speed of diagnosis. Multiple Sclerosis:Epub ahead of
print.
DOI: https://doi.org/10.1177/1352458518823955
2
https://doi.org/10.1177/1352458518823955
https://doi.org/10.1177/1352458518823955
MULTIPLE
SCLEROSIS MSJ
JOURNAL
journals.sagepub.com/home/msj 1
Multiple Sclerosis Journal
 1 –12
DOI: 10.1177/ 
13524585188239 5
© The Author(s), 2019.  
Article reuse guidelines:  
sagepub.com/journals-
permissions
Introduction
Diagnosing a patient with multiple sclerosis (MS) is a 
complex and multifaceted clinical process. However, 
the past three decades have seen a significant reduc-
tion in the time from onset of symptoms to diagnosis.1 
Probable reasons are the constantly refined diagnostic 
criteria,2 an increased magnetic resonance imaging 
(MRI) availability, and the increasing treatment 
options, approved in Switzerland since 1993. 
Nevertheless, a substantial number of patients still 
experience significant delays before receiving a defi-
nite diagnosis. A Swiss study by Kaufmann et al.3 
found that—even in recent time periods—40% of all 
newly diagnosed persons with MS reported more than 
2 years passing between symptom onset and the MS 
diagnosis. This is even more relevant in light of the 
mounting evidence on the benefits of early treatment 
initiation in relapsing remitting multiple sclerosis 
(RRMS) to prevent long-term disability.4–6
The reasons for delays in the diagnosis are not fully 
understood, and few studies have attempted more 
detailed investigations into the time from MS onset to 
diagnosis (henceforth referred to as diagnostic time).7–10 
Of these studies, most were unable to investigate the 
delaying factors using a systematic approach and 
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performed in highly specialized MS centers.7–9 An 
exception was a population-based study from Canada,10 
which found that younger age at onset and having pri-
mary progressive multiple sclerosis (PPMS) were 
associated with longer times to diagnosis.
Health system–specific aspects and care access barri-
ers may also play an important role in diagnostic 
delays. Studies from the United States found that 
insurance coverage, living in remote rural areas, and 
public transportation deficiencies can constitute sig-
nificant barriers to accessing neurological care in MS 
patients,11 which may equally apply to the diagnostic 
process.
Therefore, further investigations of delaying factors 
should not only consider clinical aspects but also pos-
sible access barriers and the diagnostic cascade poten-
tial MS patients with first symptoms take through the 
healthcare system.
Using the Swiss Multiple Sclerosis Registry (SMSR), 
we aimed to analyze the diagnostic cascade from the 
moment a patient seeks care because of first symp-
toms until a clinically isolated syndrome (CIS) or an 
MS diagnosis is confirmed. In addition, we aimed to 
analyze which setting- and patient-specific features 
potentially delay the diagnosis at the different cascade 
steps. This knowledge could lead to an optimization 
of the diagnostic process and possibly to an earlier 
start of drug and non-drug (e.g. neurorehabilitation, 
lifestyle adjustments) treatment of MS patients.
Methods
The conceptual model of the diagnostic cascade
Along the lines of the diagnostic cascade described 
by Fernández et al.,7 we developed a conceptual 
model of the diagnostic steps in collaboration with 
MS neurologists, thereby taking into account specific 
features of the Swiss healthcare system (e.g. free 
physician choice; no mandatory first visit to the pri-
mary care provider unless the health insurance plan 
requires it). This concept was subsequently used to 
guide our analysis and was the framework for sum-
marizing our study data. A sketch of the model is out-
lined in Figure 1 and includes three steps. In step 1, a 
person notices his or her symptoms and contacts a 
healthcare provider, which, in Switzerland, can be a 
general practitioner (GP) or directly a specialist. The 
contacted physician’s office then schedules a visit, 
which depending on symptom severity could take 
from a few days to months (step 2, henceforth named 
“contact-to-evaluation phase”). If, at the actual visit, 
the symptoms suggest an MS diagnosis, a neurologi-
cal referral would follow (step 3, “evaluation-to-
diagnosis phase”).
In accordance with this conceptual model, separate 
data analyses were performed to investigate the fac-
tors associated with delays in steps 2 and 3, as well as 
to summarize the variety of observed cascades over 
both steps.
The data sources
The SMSR is an ongoing, Swiss-based, patient-cen-
tered, longitudinal observational study, initiated and 
funded by the Swiss MS Society (http://www.
ClinicalTrials.gov; identifier: NCT02980640). Study 
recruitment is continuous and started in June 2016. 
Adults with CIS or confirmed MS who live or receive 
care in Switzerland can voluntarily participate. A 
wide range of measures have been implemented to 
motivate and enable Swiss persons with MS to par-
ticipate in the SMSR (described in detail by Puhan 
et al.12), such as regular information through the news 
outlets of the Swiss Multiple Sclerosis Society in the 
three main national languages, presentations to health 
care professionals and potential participants in clin-
ics and private practices, as well as the possibility to 
fill in questionnaires on paper or via a specifically 
designed online platform. At registration, a baseline 
questionnaire is completed. Afterwards, follow-up 
questionnaires can be answered on a semi-annual 
basis. The treating physician provides confirmation 
of the diagnosis. Details on the study design are 
described elsewhere.12,13
The Ethics Committee of Zurich approved the study 
(Study No. PB-2016-00894) and an informed consent 
was signed by each participant prior to study entry.12
Our analysis was restricted to patients diagnosed after 
1995 and considered all data collected until 19 March 
2018. The study utilized information from the first 
follow-up questionnaire administered 6 months post 
baseline. The baseline assessments provide informa-
tion on age, sex, lifestyle factors, education level, liv-
ing situation, year of MS diagnosis, current MS form, 
first symptoms, and family history.14 The 6-month 
follow-up questionnaire includes a comprehensive 
section on the diagnostic process. It covers the health-
care professional first contacted in connection with 
MS symptoms, details about the setting and specialty 
of the healthcare provider involved in the diagnosis, 
as well as the specialty of the healthcare provider in 
charge of the diagnostic tests. Moreover, for steps 2 
and 3 of our conceptual model, the duration of each 
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phase was assessed (contact-to-evaluation phase and 
evaluation-to-diagnosis phase, respectively).
Description of the cascade
To simplify the different cascades, we created a deci-
sion tree on the basis of our conceptual model with 
the following bifurcations to depict the diagnostic 
process steps: (1) whether a setting change occurred 
between the first contact with a physician’s office to 
the first visit (e.g. an immediate referral to a neurol-
ogy clinic by a GP office), (2) whether a neurologist 
was present at the first visit, and (3) whether the phy-
sician at the first visit led diagnostic tests, referred to 
another physician, or took no action. Setting changes 
were defined as any changes in the care setting (pri-
vate practice, hospital) and/or the specialty of the 
attending physician between the first contact and the 
first visit.
Identification of the factors associated with 
prolonged diagnostic times
In order to assess the influence of different factors on 
the diagnosis duration, we performed logistic regres-
sion models with contact-to-evaluation and evalua-
tion-to-diagnosis durations as outcome variables.
To identify prolonged diagnostic times, the contact-
to-evaluation duration was categorized into “within 
1 month” and “more than 1 month”, whereas the eval-
uation-to-diagnosis duration was categorized into 
“within 6 months” and “more than 6 months”.
The main factors (variables of interest) in the regres-
sion models were the decision tree branches with 
some modifications due to low patient numbers as 
follows. For the contact-to-evaluation duration, the 
first two bifurcations (setting change, neurologist at 
first visit) were considered, and for the evaluation-to-
diagnosis duration the last two bifurcations (neurolo-
gist at first visit, actions on clarification tests) were 
analyzed. Other fixed regression factors were sex, 
education level (mandatory education or apprentice-
ship/school leaving certificate/higher professional 
education/university degree), living in a mountainous 
area (No/Yes), MS type (RRMS start/PPMS), age at 
onset, time period of diagnosis (1996–2000/2001–
2010/2011–2018, reflecting the release years of the 
diagnostic criteria), and first visit setting (private 
practice/hospital). Potential additional factors were 
living situation, rural/urban area, language region of 
residence, Swiss nationality, MS diagnosed in older 
relatives, and 20 different first symptoms. If a first 
symptom was rare (in less than 5% of the sample), it 
was discarded (Supplemental Table S2).
For each logistic regression model, the potential fac-
tors were added to the fixed factors in a stepwise 
approach based on Akaike information criterion 
(AIC).3 Missing information (ranging from 0.1% to 
5% per variable) were imputed by means of the 
multivariate imputation by chained equations (MICE) 
algorithm.14 The entire analysis was performed using 
R, version 3.4.0.15
Results
Study population
A total of 522 participants were included (Supplemental 
Figure S1). Patients were mostly female with RRMS 
(74%), with a median age of 47 years and an Expanded 
Disability Status Scale (EDSS) score below 4 (81%). 
A detailed description of the study population is pro-
vided in Table 1.
Figure 1. The conceptual model of the diagnostic process.
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Table 1. Demographics, clinical information, and 
diagnostic process features of the included sample.
Variables Participants included in 
the regression analysesa
N 522
Age at baseline, median 
(IQR)
47 (38; 54)
Sex—female 384 (73.6%)
Disease duration at 
baseline (years)b, 
median (IQR)
7 (3; 13)
Disease duration not 
available
11 (2.1%)
MS form at baseline
 CIS 9 (1.7%)
 RRMS 384 (73.6%)
 PPMS 49 (9.4%)
 SPMS 72 (13.8%)
 Not available 8 (1.5%)
EDSS proxy at baseline
 0–3.5 420 (80.5%)
 4–6.5 68 (13%)
 7–10 32 (6.1%)
 Not available 2 (0.4%)
Contacted first doctor
 General practitioner 352 (67.4%)
 Ophthalmologist 68 (13%)
 Neurologist 44 (8.4%)
 Emergency room 34 (6.5%)
 Other specialists 23 (4.4%)
 Not available 1 (0.2%)
Time from contact with a physician to  
first symptom evaluation
 Same day/next day 96 (18.4%)
 Within 1 week 115 (22%)
 1–2 weeks 75 (14.4%)
 2–4 weeks 68 (13%)
 1–3 months 60 (11.5%)
 More than 3 months 94 (18%)
 Other 14 (2.7%)
Specialization of doctor at the first visit
  General practitioner/
internist
308 (59%)
 Neurologist 124 (23.8%)
  Other specialist (incl. 
ophthalmologist)
89 (17%)
 Not available 1 (0.2%)
Place of the first visit
 Private practice 349 (66.9%)
 Hospital 111 (21.3%)
 Emergency room 59 (11.3%)
 Not available 3 (0.6%)
Variables Participants included in 
the regression analysesa
Action on evaluation tests by the first physician
 Refer to other MD 335 (64.2%)
 Lead the tests 146 (28%)
 No action taken 35 (6.7%)
 Not available 6 (1.1%)
Next steps and visits sufficiently explained
 Yes 354 (67.8%)
 Partially 125 (23.9%)
 No 41 (7.9%)
 Not available 2 (0.4%)
Setting of further evaluation
 Outpatient 332 (63.6%)
 Inpatient 136 (26.1%)
 In- and outpatient 47 (9%)
 Not available 7 (1.3%)
Setting of diagnosis (from confirmation of diagnosis 
document)
  Neurologist in a 
hospital
267 (51.1%)
  Neurologist in a 
private practice
191 (36.6%)
  Others (general 
practitioner, …)
2 (0.6%)
 Not available 62 (11.9%)
Number of doctors visited prior to MS diagnosis
 One 34 (6.5%)
 Two 244 (46.7%)
 Three 128 (24.5%)
 More than three 114 (21.8%)
 Not available 2 (0.4%)
Time from first symptom evaluation to MS diagnosis
 Less than 1 week 87 (16.7%)
 1–2 weeks 98 (18.8%)
 2–4 weeks 78 (14.9%)
 1–3 months 101 (19.3%)
 3–6 months 48 (9.2%)
 6–12 months 34 (6.5%)
 More than 1 year 72 (13.8%)
 Other 4 (0.8%)
IQR: interquartile range; CIS: clinically isolated syndrome; 
RRMS: relapsing remitting multiple sclerosis; PPMS: primary 
progressive multiple sclerosis; SPMS: secondary progressive 
multiple sclerosis; EDSS: Kurtzke Expanded Disability Status 
Scale.
aParticipants at the 6-month follow-up, diagnosed since 1996 
and with both dependent variables available.
bThe MS duration refers to the time difference between 
the MS diagnosis date and the date of baseline survey. 
Where available, the diagnosis date was obtained from 
the diagnosis confirmation sheet provided by the treating 
physician (available for 89%). For the remainder, 
diagnosis dates were self-reported in the baseline 
questionnaires.
Table 1. (Continued)
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Description of the diagnostic cascades
Table 1 presents the details of the diagnostic process. 
During the contact-to-evaluation phase, the majority 
of patients (67%) first contacted a GP because of their 
symptoms. A minority sought care from ophthalmolo-
gists (13%), neurologists (8%), or general emergency 
services (7%). For 17% of participants, the evalua-
tion-to-diagnosis duration (step 3 in Figure 1) was 
shorter than a week, for another 53% it occurred 
within 3 months, for 16% between 3 and 12 months, 
and for the remaining 14% more than a year.
Figure 2 summarizes the first steps of the diagnostic 
process with a decision tree. Four out of five partici-
pants were seen by the physician they contacted (i.e. 
no change of setting, 78%). Of these patients, the vast 
majority (89%) did not see a neurologist at their first 
visit. By contrast, of those patients who did change 
the setting (22%), more than two out of three (68%) 
were seen by a neurologist. It is further observed from 
Figure 2 that, regardless of any prior setting change, 
neurologists were more likely to lead, perform, or 
organize diagnostic tests, while non-neurologists 
tended to refer patients to other physicians. Similar 
patterns can also be observed when the sample is 
restricted to the participants diagnosed after 2010 
(Supplemental Figure S2).
Factors associated with prolonged time from the 
first contact to symptom evaluation
Table 2 (columns 3 and 4) shows the distribution of 
all the considered, potential delaying factors for the 
contact-to-evaluation phase stratified by shorter and 
more prolonged duration. Persons with PPMS were 
more likely to wait longer for the first visit (5% in the 
Figure 2. Decision tree, from the first contact until the decisions on the clarification tests are taken.
L: lead the tests; R: refer to other medical doctor; N: no action.
Percentages displayed next to branches illustrate what population fraction within a node entered a specific branch and sum up to 100% 
for each bifurcation. Numbers indicated at each tree endpoint provide the frequency of participants who have had that combination of 
events, as well as their share (%) of the entire sample. Numbers in bold, on the right-hand side of the figure, are the most frequent action 
for each node.
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Table 2. Stratification of all factors considered for modeling the contact-to-evaluation time (columns 3 and 4) and the 
evaluation-to-diagnosis time (columns 5 and 6).
Levels Contact-to-
evaluation 
time: within 
1 month
Contact-to-
evaluation 
time: more 
than 1 month
Evaluation-
to-diagnosis 
time: within 
6 months
Evaluation-to-
diagnosis time: 
more than 
6 months
N 354 168 412 110
Diagnosis 
time period
1996–2000 42 (11.9%) 38 (22.6%) 58 (14.1%) 22 (20%)
2001–2010 150 (42.4%) 69 (41.1%) 171 (41.5%) 48 (43.6%)
After 2010 162 (45.8%) 61 (36.3%) 183 (44.4%) 40 (36.4%)
Age at onset 6–20 22 (6.2%) 8 (4.8%) 22 (5.3%) 8 (7.3%)
21–30 120 (33.9%) 41 (24.4%) 131 (31.8%) 30 (27.3%)
31–40 107 (30.2%) 50 (29.8%) 122 (29.6%) 35 (31.8%)
41–50 79 (22.3%) 43 (25.6%) 99 (24%) 23 (20.9%)
51–70 10 (2.8%) 16 (9.5%) 20 (4.9%) 6 (5.5%)
NA 16 (4.5%) 10 (6%) 18 (4.4%) 8 (7.3%)
PPMS No 336 (94.9%) 133 (79.2%) 379 (92%) 90 (81.8%)
Yes 17 (4.8%) 35 (20.8%) 32 (7.8%) 20 (18.2%)
NA 1 (0.3%) – 1 (0.2%) –
Sex Female 267 (75.4%) 117 (69.6%) 304 (73.8%) 80 (72.7%)
Male 87 (24.6%) 51 (30.4%) 108 (26.2%) 30 (27.3%)
Decision 
tree—
first two 
bifurcations
No setting change, first 
visit w/o neurologist
246 (69.5%) 115 (68.5%) – –
No setting change, first 
visit with neurologist
32 (9%) 14 (8.3%) – –
Setting change, first visit 
w/o neurologist
25 (7.1%) 12 (7.1%) – –
Setting change, first visit 
with neurologist
51 (14.4%) 27 (16.1%) – –
Decision 
tree—
last two 
bifurcations
First visit w/o neurologist, 
refer to other MD
– – 235 (57%) 69 (62.7%)
First visit w/o neurologist, 
lead the tests
– – 49 (11.9%) 10 (9.1%)
First visit w/o neurologist, 
no action
– – 18 (4.4%) 14 (12.7%)
First visit with neurologist, 
lead the tests
– – 76 (18.4%) 11 (10%)
First visit with neurologist, 
no action or refer to other 
MD
– – 29 (7%) 5 (4.5%)
NA – – 5 (1.2%) 1 (0.9%)
Living in 
mountainous 
area
No 310 (87.6%) 132 (78.6%) 354 (85.9%) 88 (80%)
Yes 41 (11.6%) 34 (20.2%) 54 (13.1%) 21 (19.1%)
NA 3 (0.8%) 2 (1.2%) 4 (1%) 1 (0.9%)
Place of first 
visit
Private practice 226 (63.8%) 123 (73.2%) 267 (64.8%) 82 (74.5%)
Hospital 126 (35.6%) 44 (26.2%) 144 (35%) 26 (23.6%)
NA 2 (0.6%) 1 (0.6%) 1 (0.2%) 2 (1.8%)
First 
symptoms 
(more than 
one possible)
Gait problems 93 (26.3%) 71 (42.3%) 125 (30.3%) 39 (35.5%)
Visual problems 135 (38.1%) 49 (29.2%) 145 (35.2%) 39 (35.5%)
Bladder problems 37 (10.5%) 21 (12.5%) 49 (11.9%) 9 (8.2%)
Balance problems 90 (25.4%) 52 (31%) 116 (28.2%) 26 (23.6%)
Bowel problems 24 (6.8%) 14 (8.3%) 29 (7%) 9 (8.2%)
Dizziness 72 (20.3%) 36 (21.4%) 86 (20.9%) 22 (20%)
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Levels Contact-to-
evaluation 
time: within 
1 month
Contact-to-
evaluation 
time: more 
than 1 month
Evaluation-
to-diagnosis 
time: within 
6 months
Evaluation-to-
diagnosis time: 
more than 
6 months
Dysarthria 25 (7.1%) 4 (2.4%) 24 (5.8%) 5 (4.5%)
Paresthesia 216 (61%) 100 (59.5%) 251 (60.9%) 65 (59.1%)
Weakness 94 (26.6%) 58 (34.5%) 117 (28.4%) 35 (31.8%)
Paralysis 87 (24.6%) 46 (27.4%) 105 (25.5%) 28 (25.5%)
Fatigue 113 (31.9%) 61 (36.3%) 137 (33.3%) 37 (33.6%)
Pain 41 (11.6%) 25 (14.9%) 52 (12.6%) 14 (12.7%)
Spasticity 22 (6.2%) 25 (14.9%) 36 (8.7%) 11 (10%)
Sexual dysfunction 17 (4.8%) 18 (10.7%) 27 (6.6%) 8 (7.3%)
Memory problems 28 (7.9%) 15 (8.9%) 33 (8%) 10 (9.1%)
Depression 32 (9%) 21 (12.5%) 37 (9%) 16 (14.5%)
Education 
level
Mandatory education/
apprenticeship
141 (39.8%) 83 (49.4%) 180 (43.7%) 44 (40%)
School leaving certificate 38 (10.7%) 7 (4.2%) 35 (8.5%) 10 (9.1%)
Higher professional 
education
54 (15.3%) 30 (17.9%) 59 (14.3%) 25 (22.7%)
University degree 105 (29.7%) 42 (25%) 121 (29.4%) 26 (23.6%)
NA 16 (4.5%) 6 (3.6%) 17 (4.1%) 5 (4.5%)
Living 
situation
With partner only 135 (38.1%) 65 (38.7%) 151 (36.7%) 49 (44.5%)
With partner and children 134 (37.9%) 55 (32.7%) 157 (38.1%) 32 (29.1%)
Alone 55 (15.5%) 39 (23.2%) 73 (17.7%) 21 (19.1%)
Other 28 (7.9%) 9 (5.4%) 29 (7%) 8 (7.3%)
NA 2 (0.6%) – 2 (0.5%)  
Language 
region of 
Switzerland
German 302 (85.3%) 135 (80.4%) 340 (82.5%) 97 (88.2%)
French 38 (10.7%) 21 (12.5%) 51 (12.4%) 8 (7.3%)
Italian 11 (3.1%) 10 (6%) 17 (4.1%) 4 (3.6%)
NA 3 (0.8%) 2 (1.2%) 4 (1%) 1 (0.9%)
MS 
diagnosed 
in older 
relatives
Yes 39 (11%) 10 (6%) 40 (9.7%) 9 (8.2%)
No 292 (82.5%) 153 (91.1%) 347 (84.2%) 98 (89.1%)
NA 23 (6.5%) 5 (3%) 25 (6.1%) 3 (2.7%)
Swiss 
citizenship
Yes 330 (93.2%) 154 (91.7%) 382 (92.7%) 102 (92.7%)
No 24 (6.8%) 14 (8.3%) 30 (7.3%) 8 (7.3%)
Typology of 
residence
Urban 196 (55.4%) 90 (53.6%) 222 (53.9%) 64 (58.2%)
Urban–rural 99 (28%) 41 (24.4%) 111 (26.9%) 29 (26.4%)
Rural 56 (15.8%) 35 (20.8%) 75 (18.2%) 16 (14.5%)
NA 3 (0.8%) 2 (1.2%) 4 (1%) 1 (0.9%)
PPMS: primary progressive multiple sclerosis; NA: not available.
Table 2. (Continued)
early group, 21% in the late group), as well as those 
with gait problems at onset (26% early, 42% late), and 
those residing in a mountainous area (12% early, 20% 
late). The contact-to-evaluation time was more often 
shorter after 2000 (88% early, 77% late), or with dys-
arthria at onset (7% early, 2% late).
Those observations were confirmed by multivariable 
logistic regression analyzing the contact-to-evaluation 
time (Figure 3). The factors associated with a shorter 
contact-to-evaluation time were diagnosis after 2000 
(odds ratio (OR): 2.1, 95% confidence interval (CI): 
[1.2; 3.8] for 2001–2010, 2.7 and [1.5; 4.8] after 
2010), having a school leaving certificate (2.4, [0.97; 
5.74]), and dysarthria at onset (3.14, [1.01; 9.77]).
PPMS (0.28, [0.14; 0.56]), gait problems at onset 
(0.6, [0.39; 0.93]), and living in a mountainous area 
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(0.58, [0.34; 1.00]) were instead associated with a 
longer time. Of note, the tree-derived levels describ-
ing the sequence of contacts were not associated with 
a prolonged time from first contact to first visit. When 
restricting the analysis to participants without PPMS, 
gait problems remained significantly associated with 
a longer contact-to-evaluation time (Supplemental 
Table S3 and Supplemental Figure S3).
Factors associated with prolonged time from 
symptom evaluation to MS diagnosis
The last two columns of Table 2 describe all potential 
delaying factors for the evaluation-to-diagnosis phase. 
Shorter times were observed more often when the 
diagnosis was after 2010 (44% early, 36% late), the 
neurologist led the tests (18% early, 10% late), or 
the first visit occurred at a hospital (35% early, 24% 
late). Prolonged durations were observed with depres-
sion as a concomitant first symptom (9% early, 15% 
late), lack of action by a non-neurologist (4% early, 
13% late), and PPMS (8% early, 18% late). These pat-
terns also emerged in the multivariable logistic regres-
sion (Figure 4).
Based on the different cascades illustrated in Figure 2, 
we further hypothesized that some cascades were 
more likely to lead to swifter diagnoses than others, 
for example, when neurologists are almost immedi-
ately involved in diagnosis. Indeed, the multivariable 
model indicated that the evaluation-to-diagnosis 
duration was statistically significantly faster when a 
neurologist led the clarification tests, compared to 
patients first seeing a GP and then being referred 
(OR 2.21 [1.07; 4.59]). Moreover, a diagnosis year 
after 2010, compared with one before 2000, was also 
associated with faster evaluation-to-diagnosis times 
(1.96, [1.03; 3.74]). By contrast, having PPMS (0.28, 
[0.14; 0.56]), depression as a concomitant first symp-
tom (0.46, [0.24; 0.91]), higher professional educa-
tion (0.49, [0.27; 0.91]), or seeing a (non-neurologist) 
physician who did not undertake further diagnostic 
actions (0.28, [0.13; 0.62]) were all associated with a 
prolonged evaluation-to-diagnosis phase.
Figure 3. Regression coefficients of the multivariable model on the contact-to-evaluation time.
ref.: reference level; PPMS: primary progressive multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; Priv. Practice: private 
practice; SC: setting change.
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Figure 4. Regression coefficients of the multivariable model on the evaluation-to-diagnosis time.
ref.: reference level; PPMS: primary progressive multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; Priv. Practice: private 
practice; neurol.: neurologist.
Discussion
Using comprehensive questionnaire data from 522 
Swiss MS Registry participants, we described the MS 
diagnosis process for persons receiving care in 
Switzerland. Our study analyzed in detail the steps 
after the first contact and identified the delaying 
factors.
We observed a broad variety of possibilities on how 
potential MS patients entered the healthcare system 
(Supplemental Table S1), but overall the cascade 
functioned as expected (Figure 2).
GPs were contacted primarily, and they usually 
referred patients to a neurologist who led further diag-
nostic tests and finally made the diagnosis. Importantly, 
this procedure did not prolong the overall diagnostic 
process compared to patients immediately contacting 
a neurologist, unless no action was taken. By contrast, 
the type of MS or first symptoms were more crucial in 
prolonging the process. Specifically, gait problems 
were associated with a longer time from the first con-
tact to the first visit and dysarthria with a shorter one. 
The concomitance of depression was associated with a 
longer time from the first visit to the diagnosis and 
having PPMS was the most influential factor for a pro-
longed diagnosis duration and negatively influenced 
both phases.
To our knowledge, few studies have explored the 
diagnostic pathways and the role of patient-, dis-
ease-, and setting-specific aspects in MS diagnosis 
duration.7–10 Fernández et al.7 identified delays in sev-
eral steps leading up to an MS diagnosis (onset to first 
visit, first visit to referral, time to perform the tests) 
and found the phase from the first symptoms to the 
first visit to be particularly critical. Kelly et al. found 
that approximately 78% of patients saw a neurologist 
within 6 weeks from onset, in accordance with UK 
guidelines. They also provided a list of common rea-
sons for delay.8
Detailed examinations of factors delaying the diag-
nostic process were, however, largely missing. For 
example, Marrie et al.1,16 examined the effect of 
single factors, namely, onset year and comorbidities. 
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Kingwell et al. pursued a systematic approach to iden-
tify the factors associated with the diagnostic time, 
but did not include sociodemographic factors, access 
barriers, and features of the diagnostic cascade in 
their assessment. Recently, Kaufmann et al.3 investi-
gated this question using SMSR data, but without dis-
tinguishing between the different diagnostic process 
phases, instead modeling the whole diagnostic time at 
once.
This study extends these prior efforts by analyzing the 
different steps of the cascade in greater detail and test-
ing a broader array of factors potentially delaying the 
diagnosis. Our findings may add to the literature by 
emphasizing the role of symptom presentation for a 
swift MS diagnosis. In particular, the concomitant 
occurrence of depression at onset (in 10% of the study 
population) as a delaying factor confirms the results 
of Marrie et al.16 There are various explanations: 
depression appears highly heterogeneous and is not 
considered a specific MS symptom, the patients them-
selves might not seek care due to an inability to take 
action, and the physician might interpret organic 
symptoms as psychogenic due to depression.
The delaying effect of gait problems might appear to 
contradict the findings of Kaufmann et al.,3 where 
they were associated with a quicker diagnostic pro-
cess. However, in our study, gait problems were asso-
ciated with a longer contact-to-evaluation phase, but 
not a longer evaluation-to-diagnosis phase. Gait prob-
lems often occur slowly, especially in patients with 
PPMS, and are therefore not urgent symptoms trig-
gering immediate examinations, despite being dis-
tinctive first MS symptoms (Supplemental Table S3).
Furthermore, the fact that the diagnostic cascade was 
shorter every time the main diagnostic criteria were 
released (2001, 2010) extends Marrie et al.’s1 findings 
on a more recent timeframe.
Our finding of longer diagnostic times in patients with 
PPMS confirms those reported in other studies.3,10 The 
delaying effect of having PPMS on the time from the 
first evaluation to diagnosis possibly reflects the 
requirement of McDonald diagnostic criteria, which 
require 1 year of confirmed progression for this MS 
type. However, because delays in PPMS were also 
statistically significantly longer in the first phase of 
the diagnostic cascade (i.e. before the first evalua-
tion), this suggests that at least a part of the delay 
occurs independently of the diagnostic criteria 
applied. For example, it is possible that the nature of 
symptoms in PPMS is less disruptive and urgent when 
compared to those that predominate in RRMS, thus 
already leading to delayed care seeking after the first 
symptom occurrence.
From a healthcare utilization perspective, specific 
sociodemographic factors could represent care access 
barriers hindering the diagnostic process.11 However, 
our findings revealed that most factors potentially 
constituting a barrier, such as lower education, living 
in an urban area, or having a migration background, 
do not lead to a prolonged diagnosis. Only living in 
mountainous areas was associated with longer diag-
nosis durations, probably due to a shortage of neurol-
ogists in those areas. But overall, our findings suggest 
that there is a good healthcare access, due to the Swiss 
mandatory healthcare insurance, a high hospital 
capacity,17 and diffuse hospital vicinity,18 resulting in 
a reasonably fast diagnostic process.19
Strengths and limitations
To better understand during which diagnostic cascade 
phase delays can occur, we differentiated the diagnos-
tic process into two phases. Referring to more objec-
tive events (e.g. first contact, first visit) rather than 
personal interpretations (e.g. onset date) made our 
outcomes less prone to recall bias and subjectivity.
Moreover, the available information of the SMSR, 
such as education level, circumstances of life, and 
family history, is more comprehensive than other sim-
ilar studies,20,21 and adjusting for them contributes to 
the findings’ robustness. In addition, having precise 
information on a large variety of different first symp-
toms allowed us to indicate which symptoms should 
be better monitored to prevent delays.
While some of our findings are setting specific (e.g. 
the distribution of primary care contacts), others are 
likely to generalize to other settings. For example, the 
diffuse nature of some of the MS symptoms associ-
ated with delays is likely also of concern in other 
countries.
This study presents, however, some limitations. First, 
self-reported data can be affected by biases, such as 
recall bias and underreporting. Moreover, we did not 
include information on comorbidities other than 
depression at the time of the onset that were previ-
ously found to contribute to delays.16
In addition, diagnostic delays can also occur due to 
financial access barriers, even in countries with social 
health insurance systems like Switzerland (e.g. due to 
high out-of-pocket expenses and upfront payments22,23). 
Unfortunately, we were unable to assess the actual 
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financial situation of the participants, so we used the 
education level as a proxy instead.
Prospect for future research
To accelerate the diagnostic process further, future 
research should examine the reasons why patients 
may not seek immediate care after the first onset of 
MS symptoms. Moreover, the potential causes for ini-
tial inactivity by first healthcare providers deserve 
further investigation and may lie in unusual symptom 
combinations, lack of awareness for MS, or problems 
in patient–doctor communication.
Conclusion
Our study is among the first to query persons with 
MS on how they responded after noticing their first 
symptoms. This effort has provided a comprehensive 
picture of the patients’ first steps in the healthcare 
system toward an MS diagnosis after symptom onset, 
which was unknown until now in Switzerland. The 
observation that the majority of Swiss MS patients 
were diagnosed in a timely manner regardless of set-
ting and specialty of first physician contact is reas-
suring, but still too many potentially preventable 
delays occur in these first steps until diagnosis initia-
tion. For a faster diagnostic process, awareness for 
MS as a differential diagnosis of gait disorders should 
be raised, and an attentive follow-up of possible MS 
cases with depression as a concomitant first symptom 
is needed.
Acknowledgements
The authors wish to thank the Swiss Multiple 
Sclerosis Society for funding the Swiss MS Registry. 
Moreover, we thank the study participants who not 
only contributed data but also were absolutely instru-
mental in all aspects of study design and conduct of 
the Swiss Multiple Sclerosis Registry. We further 
thank the members of the SMSR Data Center at the 
Epidemiology, Biostatistics and Prevention Institute 
of the University of Zurich. Members of the Swiss 
Multiple Sclerosis Registry are Bernd Anderseck, 
Pasquale Calabrese, Andrew Chan, Giulio Disanto, 
Britta Engelhardt, Claudio Gobbi, Roger Häussler, 
Christian P Kamm, Susanne Kägi, Jürg Kesselring 
(President), Jens Kuhle (Chair of Clinical and 
Laboratory Research Committee), Roland Kurmann, 
Christoph Lotter, Kurt Luyckx, Doron Merkler, 
Patricia Monin, Stephanie Müller, Krassen 
Nedeltchev, Caroline Pot, Milo A Puhan, Irene 
Rapold, Anke Salmen, Sven Schippling, Claude 
Vaney (Chair of Patient- and Population Research 
Committee), and Viktor von Wyl (Chair of IT and 
Data Committee). L.B. and C.P.K. have contributed 
equally.
Declaration of Conflicting Interests
The author(s) declared the following potential con-
flicts of interest with respect to the research, author-
ship, and/or publication of this article: C.G., H.D., 
J.K., L.B., M.K., M.A.P., N.S., S.R., V.A.-G., and 
V.v.W. have nothing to disclose. A.C. has received 
compensation for activities (speaker, boards) with 
Actelion, Almirall, Bayer, Biogen, Celgene, Genzyme, 
Merck, Novartis, Roche, and Teva, all for university 
research funds and research support from UCB and 
Genzyme. A.S. has received speaker honoraria and/or 
travel compensation for activities with Almirall 
Hermal GmbH, Biogen, Merck, Novartis, Roche, and 
Sanofi Genzyme, none related to this work. C.P. has 
received travel support and participated in the advi-
sory board for Biogen Idec, Genzyme, Novartis, and 
Roche. C.P.K. has received honoraria for lectures as 
well as research support from Biogen, Novartis, 
Almirall, Bayer Schweiz AG, Teva, Merck, Sanofi 
Genzyme, Roche, Celgene, and the Swiss MS Society. 
P.C. has received honoraria for speaking at scientific 
meeting, serving at scientific advisory boards, and 
consulting activities from Abbvie, Actelion, Almirall, 
Bayer-Schering, Biogen Idec, EISAI, Genzyme, 
Lundbeck, Merck Serono, Novartis, Pfizer, Teva, and 
Sanofi-Aventis; his research was also supported by 
the Swiss Multiple Sclerosis Society, the Swiss 
National Research Foundation, and the SOFIA 
Foundation. S.M. received honoraria for travel, hono-
raria for lectures/consulting, and/or grants for studies 
from Almirall, Biogen, Celgene, Novartis, Teva, 
Merck Serono, Genzyme, Roche, and Bayer Schweiz 
AG. S.S. was supported by the Swiss National Science 
Foundation, the Clinical Research Priority Program 
of the University of Zurich, the Myelin Repair 
Foundation, and the Swiss Multiple Sclerosis Society 
and has received research grants from Novartis and 
Sanofi Genzyme and consultancy and speaker fees 
from Biogen, Merck Serono, Novartis, Roche, Sanofi 
Genzyme, and Teva.
Funding
The author(s) disclosed receipt of the following finan-
cial support for the research, authorship, and/or publi-
cation of this article: This work was supported by the 
Swiss Multiple Sclerosis Society.
Supplemental Material
Supplemental material for this article is available 
online.
Multiple Sclerosis Journal 00(0)
12 journals.sagepub.com/home/msj
ORCID iDs
Laura Barin  https://orcid.org/0000-0001-8139-4686
Marco Kaufmann  https://orcid.org/ 0000-0002- 
4810-7734
References
 1. Marrie RA, Cutter G, Tyry T, et al. Changes in the 
ascertainment of multiple sclerosis. Neurology 2005; 
65: 1066–1070.
 2. Thompson AJ, Banwell BL, Barkhof F, et al. 
Diagnosis of multiple sclerosis: 2017 revisions of the 
McDonald criteria. Lancet Neurol 2018; 17: 162–173.
 3. Kaufmann M, Kuhle J, Puhan MA, et al. Factors 
associated with time from first symptoms to diagnosis 
and treatment initiation of multiple sclerosis in 
Switzerland. Mult Scler J Exp Transl Clin 2018; 4: 
1–10.
 4. Comi G, Radaelli M and Soelberg Sørensen P. 
Evolving concepts in the treatment of relapsing 
multiple sclerosis. Lancet 2017; 389: 1347–1356.
 5. Chalmer TA, Baggesen LM, Nørgaard M, et al. Early 
versus later treatment start in multiple sclerosis: A 
register-based cohort study. Eur J Neurol 2018; 25: 
1262-e110.
 6. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. 
Brain health: Time matters in multiple sclerosis. Mult 
Scler Relat Dis 2016; 9: S5–S48.
 7. Fernández O, Fernandez V, Arbizu T, et al. 
Characteristics of multiple sclerosis at onset and 
delay of diagnosis and treatment in Spain (The Novo 
Study). J Neurol 2010; 257: 1500–1507.
 8. Kelly S, Chaila E, Kinsella K, et al. Multiple sclerosis, 
from referral to confirmed diagnosis: An audit of 
clinical practice. Mult Scler 2011; 17: 1017–1021.
 9. Adamec I, Barun B, Gabelić T, et al. Delay in the 
diagnosis of multiple sclerosis in Croatia. Clin Neurol 
Neurosur 2013; 115: S70–S72.
 10. Kingwell E, Leung AL, Roger E, et al. Factors 
associated with delay to medical recognition in two 
Canadian multiple sclerosis cohorts. J Neurol Sci 
2010; 292: 57–62.
 11. Minden S, Frankel D, Hadden L, et al. Access to 
health care for people with multiple sclerosis. Mult 
Scler 2007; 13: 547–558.
 12. Puhan MA, Steinemann N, Kamm CP, et al. A 
digitally facilitated citizen-science driven approach 
accelerates participant recruitment and increases 
study population diversity. Swiss Med Wkly 2018; 
148: w14623.
 13. Steinemann N, Kuhle J, Calabrese P, et al. The Swiss 
Multiple Sclerosis Registry (SMSR): Study protocol 
of a participatory, nationwide registry to promote 
epidemiological and patient-centered MS research. 
BMC Neurol 2018; 18: 111.
 14. Barin L, Salmen A, Disanto G, et al. The disease 
burden of multiple sclerosis from the individual 
and population perspective: Which symptoms 
matter most? Mult Scler Relat Dis 2018; 25: 
112–121.
 15. R Core Team L. R: A language and environment 
for statistical computing. Vienna: R Foundation for 
Statistical Computing, 2017, http://www.r-project 
.org/
 16. Marrie RA, Horwitz R, Cutter G, et al. Comorbidity 
delays diagnosis and increases disability at diagnosis 
in MS. Neurology 2009; 72: 117–124.
 17. Herzlinger R and Parsa-Parsi R. Consumer-driven 
health care lessons from Switzerland. JAMA 2004; 
292: 1213–1220.
 18. Berlin C, Panczak R, Hasler R, et al. Do acute 
myocardial infarction and stroke mortality vary by 
distance to hospitals in Switzerland? Results from the 
Swiss National Cohort Study. BMJ Open 2016; 6: 
e013090.
 19. Barin L, Kaufmann M, Salmen A, et al. Patterns 
of care for multiple sclerosis in a setting of 
universal care access: A cross-sectional study from 
Switzerland. Mult Scler Relat Dis 2019; 28: 17–25.
 20. Calabrese P, Kobelt G, Berg J, et al. New insights 
into the burden and costs of multiple sclerosis in 
Europe: Results for Switzerland. Mult Scler 2017; 23: 
192–203.
 21. Lorscheider J, Benkert P, Lienert C, et al. 
Comparative analysis of natalizumab versus 
fingolimod as second-line treatment in relapsing–
remitting multiple sclerosis. Mult Scler 2018; 24: 
777–785.
 22. Reinhardt UE. The Swiss health system: Regulated 
competition without managed care. JAMA 2004; 292: 
1227–1231.
 23. Osborn R, Doty MM, Moulds D, et al. Older 
Americans were sicker and faced more financial 
barriers to health care than counterparts in other 
countries. Health Affair 2017; 36: 2123–2132.
Visit SAGE journals online 
journals.sagepub.com/
home/msj
 SAGE journals
